Objectives Thyroid hormone suppression therapy has been widely used in the treatment of
thyroid cancer, but concerns have been raised about the cardiovascular risks of this …

Purpose The primary aim was to study the risk of cardiovascular mortality in patients with
differentiated thyroid carcinoma (DTC). Secondary aims were to evaluate all-cause mortality …

Introduction To minimize recurrence risk in differentiated thyroid cancer (DTC), TSH is
usually lifelong suppressed with levothyroxine. A common consequence of this treatment is …

Context The incidence of differentiated thyroid cancer (DTC) is increasing, yet the prognosis
is favourable and long‐term survival is expected. Exogenous TSH suppression has been …

Context Thyroid dysfunction is associated with an increased risk of cardiovascular disease
(CVD) in the general population; however, it remains controversial whether differentiated …

Background: Patients with differentiated thyroid carcinoma (DTC) have a favorable
prognosis after treatment with thyroidectomy, radioiodine, and TSH suppression. However …

Objective Many thyroid cancer patients are exposed to long-term thyroid-stimulating
hormone (TSH) suppression, often as lifetime treatment, and are consequently at risk for …

Introduction: Long-term cardiovascular (CV) risk is a concern for differentiated thyroid cancer
(DTC) survivors. Methods: We performed a systematic review and meta-analysis evaluating …

Background Differentiated thyroid cancer (DTC) occurs in relatively young patients and is
associated with a good prognosis and long survival. The management of this disease …

Differentiated thyroid cancer is the most common form of thyroid cancer and its prognosis is
favourable in most cases. Suppression of thyroid stimulating hormone (TSH) by supra …